Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Bausch Health has strengthened its focus on myopia research through an exclusive license agreement with BHVI for myopia control contact lenses. This partnership aims to develop lenses that may slow myopia progression in children, addressing a growing global health issue projected to affect 50% of the population by 2050. Earlier, Bausch + Lomb secured another licensing agreement with Eyenovia for a pediatric myopia treatment. CEO Joseph C. Papa emphasizes the commitment to innovative solutions for this increasing ocular disorder.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its gastroenterology division, Salix Pharmaceuticals, will present five scientific posters at the United European Gastroenterology (UEG) Week Virtual 2020 from Oct. 11-13, 2020. The presentations focus on innovative treatments addressing gastrointestinal diseases, specifically featuring studies on Rifaximin and Plecanatide related to conditions such as irritable bowel syndrome and chronic liver disease. Salix's commitment to research underscores its role as a leader in gastroenterology and aims to provide valuable insights for healthcare providers.
Bausch Health Companies Inc. (NYSE/TSX: BHC) provided a preliminary update on its third-quarter 2020 results, anticipating revenues exceeding $2.1 billion, a 28% sequential increase from Q2 2020. Despite this growth, revenue is expected to decline about 3% compared to Q3 2019. For the full year, the company estimates revenues between $7.80 and $8.00 billion, with Adjusted EBITDA expected between $3.15 and $3.30 billion.
Full financial results will be released on Nov. 3, 2020, along with a conference call.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its Bausch + Lomb INFUSE™ silicone hydrogel daily disposable contact lenses will be featured in three poster presentations during the virtual American Academy of Optometry Annual Meeting from Oct. 7-22, 2020. The company has received positive feedback for the lenses since their launch in August, highlighting their comfort and performance. The research will cover various assessments, including the lens's dehydration resistance and its ability to mitigate contact lens dryness, aiming to enhance wearer experience.
Bausch Health Companies Inc. (BHC) announced the launch of LiverHEalthNow, an online resource aimed at improving the detection and management of Overt Hepatic Encephalopathy (OHE) in chronic liver disease patients. This initiative coincides with Liver Awareness Month and aims to educate healthcare providers and patients. Approximately 30 million Americans are affected by liver disease, with OHE being a severe complication. Salix Pharmaceuticals, part of Bausch Health, emphasizes the importance of early detection to improve patient outcomes and reduce hospital readmissions.
Bausch Health's LUMIFY® Eye Drops Honored in Nielsen's 2020 Top 25 Breakthrough Innovations
On October 1, 2020, Bausch Health Companies Inc. (BHC) announced that its LUMIFY redness reliever eye drops were recognized in the "Superstar" category by BASES, a Nielsen Global Consumer division, for outstanding sales and market growth. Launched in 2018, LUMIFY has secured a 40% market share among redness relievers and is the top recommended brand by eye doctors. This accolade highlights LUMIFY's effectiveness and innovative marketing, driving significant category growth and consumer engagement.
Bausch Health Companies Inc. announced that its ophthalmic solution, VYZULTA (latanoprostene bunod), has received regulatory approval in Ukraine, increasing its market reach to seven countries including the United States and Canada. In Canada, VYZULTA is now publicly reimbursed in multiple provinces. Moreover, Medicare Part D coverage in the U.S. rose to approximately 45% from 30%. The treatment is aimed at reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company aims to secure more approvals globally.
Bausch Health Companies released its 2019 Corporate Social Responsibility (CSR) Report, emphasizing its commitment to ethical and sustainable business practices. The report discusses the company's initiatives in five key areas: integrity, environmental respect, global health, community improvement, and employee well-being. Significant highlights include reductions in energy and carbon emissions, established an Energy Efficiency Group, and continued responsible pricing strategies with average annual price increases capped at single digits. The company also outlines its response to COVID-19 and ongoing diversity and inclusion efforts.
Bausch Health Companies Inc. (BHC) has resolved intellectual property disputes with Sun Pharmaceutical regarding XIFAXAN® (rifaximin) 200 mg and 550 mg tablets, maintaining market exclusivity until 2028. Under the agreement, Sun will receive a non-exclusive license to market generic versions effective January 1, 2028, pending FDA approval. The litigation will be dismissed, and all intellectual property for XIFAXAN remains intact, with 26 patents securing its market position. Final patent expirations are set for July and October 2029.
Bausch Health has announced an agreement to acquire an option to purchase all ophthalmology assets from Allegro Ophthalmics, including global rights to risuteganib, an investigational treatment for dry age-related macular degeneration (AMD). The acquisition is valued at $50 million, with a $10 million initial payment and a contingent $40 million payment expected in 2021. Risuteganib targets multiple pathways involved in AMD, addressing a significant unmet medical need affecting millions globally. The acquisition aligns with Bausch Health's strategy to enhance its pipeline in eye health.